Intravesical instillation with live, attenuated Mycobacterium Bacillus Calmette-Guérin (BCG ... criticize the suboptimal monthly maintenance regimen in the BCG arm and the low concentration ...
Pfizer's Phase III CREST trial evaluating sasanlimab with Bacillus Calmette-Guérin (BCG), as induction treatment with or without maintenance in subjects with BCG-naïve, high-risk non-muscle ...
an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve ...
Among patients with Bacillus Calmette-Guérin (BCG)-naïve ... statistically significant improvement in event-free survival associated with induction and maintenance treatment with the combination ...
an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance for BCG-naïve, high-risk non-muscle ...
The phase 3 trial enrolled people with high-risk, non-muscle invasive bladder cancer (NMIBC) who were yet to try Bacillus Calmette-Guérin ... later received BCG as a maintenance therapy.
Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback